Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €61.24 EUR
Change Today -0.393 / -0.64%
Volume 12.3K
ZEG On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 10:56 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

AstraZeneca PLC, a biopharmaceutical company, engages in the discovery, development, manufacturing, and marketing of prescription medicines. The company operates in approximately 100 countries. The company focuses on three major areas of the healthcare, such as cardiovascular and metabolic diseases; oncology; and respiratory, inflammation, and autoimmunity. It is also active in the infection, neuroscience, and gastrointestinal disease areas. Cardiovascular and Metabolic Diseases Marketed Products Cardiovascular Disease Atacand/Atacand HCT/Atacand Plus (candesartan cilexetil) is an angiotensin II antagonist for the 1st line treatment of hypertension and symptomatic heart failure. Brilinta/Brilique (ticagrelor) is an oral antiplatelet for acute coronary syndromes (ACS). Crestor2 (rosuvastatin calcium) is a statin for dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and reduce the risk of first cardiovascular events. Plendil (felodipine) is a calcium antagonist for hypertension and angina. Seloken/Toprol-XL (metoprolol succinate) is a beta-blocker once daily tablet for 24-hour control of hypertension, and heart failure and angina. Tenormin (atenolol) is a cardioselective beta-blocker for hypertension, angina pectoris and other cardiovascular disorders. Zestril (lisinopril dihydrate) is an angiotensin-converting enzyme inhibitor for a range of cardiovascular diseases, including hypertension. Metabolic Disease Byetta (exenatide injection) is an injectable medicine indicated to improve blood sugar (glucose) control, along with diet and exercise in adults with Type 2 diabetes mellitus. Bydureon (exenatide extended-release for injectable suspension) is a once weekly injectable medicine indicated to improve blood sugar (glucose), along with diet and exercise in adults with Type 2 diabetes mellitus. Bydureon Pen (exenatide extended-release for injectable suspension) delivers exenatide through microsphere technology in a once weekly dose requiring no titration. Farxiga/Forxiga (dapagliflozin) is a selective inhibitor of human sodium-glucose co-transporter 2 (SGLT-2 inhibitor) to improve glycaemic control in adult patients with Type 2 diabetes mellitus. Kombiglyze XR (saxagliptin and metformin XR) combines saxagliptin (Onglyza) and metformin extended release metformin (metformin XR) in a once daily tablet for Type 2 diabetes mellitus. Komboglyze (saxagliptin and metformin HCl) combines saxagliptin (Onglyza) and metformin immediate release (metformin IR) in a twice daily tablet for Type 2 diabetes mellitus. Myalept5 (metreleptin for injection) is a recombinant analogue of human leptin indicated in the United States of America (U.S.) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy. Onglyza (saxagliptin) is an oral dipeptidyl peptidase 4 (DPP-4) inhibitor for Type 2 diabetes mellitus. Symlin (pramlintide acetate) is an injected amylin analogue for Type 1 and Type 2 diabetes mellitus in patients with inadequate glycaemic control on meal time insulin. Xigduo (dapagliflozin and metformin hydrochloride) combines dapagliflozin (Farxiga/Forxiga), an SGLT-2 inhibitor, and metformin hydrochloride, in a twice daily tablet to improve glycaemic control in adult patients with Type 2 diabetes mellitus who are inadequately controlled by metformin alone. Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) combines dapagliflozin (Farxiga/Forxiga), an SGLT-2 inhibitor, and metformin hydrochloride extended-release, in a once daily tablet to improve glycaemic control in adult patients with Type 2 diabetes mellitus who are inadequately controlled by metformin alone. The company’s strategy in cardiovascular and metabolic diseases focuses on maximising and maintaining patient benefit from its portfolio of medicines, ensuring access to Brilinta/Brilique and accelerating clinical programmes and potential new therapies through innovative science and collaboration. The company is investing

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €61.24 EUR -0.393

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €88.83 EUR -0.82
Biogen Inc $386.22 USD +12.29
Celgene Corp $110.55 USD +2.49
Eli Lilly & Co $73.12 USD +1.25
Valeant Pharmaceuticals International Inc C$271.19 CAD +9.56
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 66.8x
Price/Sales 3.3x
Price/Book 5.0x
Price/Cash Flow 66.7x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.